Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 2 | 0 | 1 | 0 | 0 |
Analyst Firms Making Recommendations1
- Ladenburg Thalmann
- SVB Leerink
- HC Wainwright & Co.
- Wells Fargo
- William Blair
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Calithera Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/15/2022 | CALA | Buy Now | Calithera Biosciences | $0.03 | — | Ladenburg Thalmann | Aydin Huseynov | — | Downgrade | Buy → Neutral | Get Alert |
| 11/15/2022 | CALA | Buy Now | Calithera Biosciences | $0.03 | 6034.97% | SVB Leerink | Jonathan Chang | $18 → $2 | Downgrade | Outperform → Market Perform | Get Alert |
| 08/29/2022 | CALA | Buy Now | Calithera Biosciences | $0.03 | 24439.88% | HC Wainwright & Co. | Swayampakula Ramakanth | → $8 | Upgrade | Neutral → Buy | Get Alert |
| 08/16/2022 | CALA | Buy Now | Calithera Biosciences | $0.03 | 55114.72% | SVB Leerink | Jonathan Chang | $2 → $18 | Maintains | Outperform | Get Alert |
| 05/11/2022 | CALA | Buy Now | Calithera Biosciences | $0.03 | 6034.97% | Wells Fargo | Nick Abbott | $60 → $40 | Maintains | Equal-Weight | Get Alert |
| 04/04/2022 | CALA | Buy Now | Calithera Biosciences | $0.03 | 6034.97% | SVB Leerink | Jonathan Chang | $60 → $40 | Maintains | Outperform | Get Alert |
| 01/31/2022 | CALA | Buy Now | Calithera Biosciences | $0.03 | 12169.94% | Ladenburg Thalmann | Aydin Huseynov | → $80 | Initiates | → Buy | Get Alert |
| 01/20/2022 | CALA | Buy Now | Calithera Biosciences | $0.03 | 9102.45% | SVB Leerink | Jonathan Chang | $20 → $60 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/08/2021 | CALA | Buy Now | Calithera Biosciences | $0.03 | — | HC Wainwright & Co. | Swayampakula Ramakanth | — | Downgrade | Buy → Neutral | Get Alert |
| 11/05/2021 | CALA | Buy Now | Calithera Biosciences | $0.03 | — | William Blair | Matt Phipps | — | Downgrade | Outperform → Market Perform | Get Alert |
| 01/05/2021 | CALA | Buy Now | Calithera Biosciences | $0.03 | 12169.94% | HC Wainwright & Co. | — | — | Maintains | Buy | Get Alert |
| 01/05/2021 | CALA | Buy Now | Calithera Biosciences | $0.03 | 6034.97% | SVB Leerink | Jonathan Chang | — | Downgrade | Outperform → Market Perform | Get Alert |
What is the target price for Calithera Biosciences (CALA)?
The latest price target for Calithera Biosciences (OTCEM: CALA) was reported by Ladenburg Thalmann on November 15, 2022. The analyst firm set a price target for $0.00 expecting CALA to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Calithera Biosciences (CALA)?
The latest analyst rating for Calithera Biosciences (OTCEM: CALA) was provided by Ladenburg Thalmann, and Calithera Biosciences downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for Calithera Biosciences (CALA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Calithera Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Calithera Biosciences was filed on November 15, 2022 so you should expect the next rating to be made available sometime around November 15, 2023.
Is the Analyst Rating Calithera Biosciences (CALA) correct?
While ratings are subjective and will change, the latest Calithera Biosciences (CALA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Calithera Biosciences (CALA) is trading at is $0.03, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.